KPV dosage and evidence

What is KPV?

How does KPV work?

It gets inside cells and turns down NF-kB, a main switch for swelling. That lowers the swelling signals the cell sends out.

What have studies in people found about KPV?

There is no evidence in people for KPV. None. In 2026, FDA searched for it as part of a formal review. It found no studies in people, no case reports and no record of anyone taking it by any route. It said so in two separate documents.

• FDA review of KPV, 12 May 2026: the request to allow KPV in compounding cited nine sources for wound healing and inflammation. Eight were animal studies of related compounds. One tested how well it soaks into skin taken from dead bodies. In FDA's words, none were studies of KPV given to people.
• FDA then ran its own search of the main medical and drug databases, including PubMed and ClinicalTrials.gov. It found no data, such as studies, on the use of KPV in people.
• No case reports either. FDA checked its side effect reporting system and its food complaint records, and found no reports of KPV use in people. It also found no data in people on immune reactions or on the peptide clumping.
• No pharmacy record. Large compounding pharmacies reported making no products with KPV for FDA between January 2017 and June 2025. Even the pharmacy trail is empty.
• FDA's recommendation: on balance, KPV should not be added to the list of substances pharmacies may compound. Its reasons were that KPV is poorly described chemically, nobody knows how much it is used, and what FDA calls non-existing information on its use in people.
• FDA's safety page on compounding substances, updated 22 April 2026, says in one sentence what the 29-page review shows: FDA has found no data on anyone taking a product with KPV, by any route.
• No registered trials. ClinicalTrials.gov lists no study of KPV.
• The only test using human tissue is about delivery, not effect. KPV dissolves in water at 0.7 mg/mL. A lab test on skin from dead bodies found it does not soak in well. FDA notes that could limit it as a skin cream, because it may not reach the deeper skin layers.

What this does not tell you: Nothing is known about what KPV does in a person, at what dose, by what route, for how long, or with what risk, because nobody has given it to one and written it down. The results in mice with gut inflammation are real results in mice. The work on gut and immune cells in dishes is real lab work. Repeating either does not turn it into human evidence. Having no human data is not a safety finding either way. It does not mean the peptide is dangerous, and it does not mean it is safe. It means nobody has asked.

The state of the research

The evidence, in charts

The studies we cite

• Review of studies2026
  July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee

  The official record of the meeting where KPV was considered for the list of ingredients compounding pharmacies may use. The panel voted 8 to 6 to back it, against the FDA reviewers. The vote is only advice.

  Official record of the meeting at which KPV was considered for the 503A bulks list; the committee's 8 to 6 vote to recommend it went against FDA reviewers' position and is advisory only.

  Source U.S. FDA (Advisory Committee Calendar)
• Review of studies2026
  FDA Evaluation of KPV-Related Bulk Drug Substances (KPV (Free Base) and KPV acetate)

  A regulator went looking for human evidence on KPV and found none at all. The people who nominated KPV supplied nine references. Eight were animal studies of related compounds and one used skin taken from cadavers. None gave KPV to a living person. FDA then searched the medical databases, its own side effect reports and pharmacy records, and found no studies, no case reports and nothing on safety. It recommended against adding KPV to the compounding list.

  FDA's full search of the human record for KPV. The nomination cited nine references, eight of them animal studies of alpha-MSH derivatives and one a cadaver-skin permeation study, and none of KPV administered in humans. FDA's own search identified no clinical studies in humans, no case reports, and no immunogenicity data, and outsourcing facilities reported no KPV preparations from January 2017 to June 2025. FDA proposed not adding KPV to the 503A bulks list.

  Source U.S. Food and Drug Administration, CDER briefing document, May 12, 2026
• Review of studies2026
  Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

  One sentence from a regulator carries the whole human record: there is not one. FDA states it has identified no human exposure data on any product containing KPV, by any route of administration. That is the finding. Nobody has taken it and written down what happened, so nothing is known about dose, effect or harm. An empty record is not evidence of safety in either direction.

  FDA states it has not identified any human exposure data on drug products containing KPV administered via any route of administration, and lacks important information regarding any safety issues raised by KPV including whether it would cause harm if administered to humans. Updated 22 April 2026.

  Source U.S. Food and Drug Administration
• Animal study2008
  PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

  In mice with colitis, KPV by mouth eased the gut inflammation. It got into gut cells through a carrier called PepT1. In a dish, tiny amounts turned down swelling signals in gut cells and immune cells.

  Nanomolar KPV inhibited NF-kappaB and MAP kinase signaling in intestinal epithelial and T cells, and oral KPV reduced DSS- and TNBS-induced colitis in mice via the PepT1 transporter.

  PMID 18061177 Gastroenterology
• Animal study2017
  Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis

  In mice with colitis, KPV carried in tiny particles sped up healing of the gut lining and lowered a swelling signal called TNF-alpha.

  Nanoparticle-delivered KPV accelerated mucosal healing and lowered TNF-alpha in a mouse colitis model.

  PMID 28143741 Molecular Therapy